FY2030 Earnings Estimate for MediWound Issued By Maxim Group

MediWound Ltd. (NASDAQ:MDWD) – Equities research analysts at Maxim Group reduced their FY2030 earnings per share (EPS) estimates for shares of MediWound in a report issued on Friday, May 29th. Maxim Group analyst M. Okunewitch now anticipates that the biopharmaceutical company will earn $2.81 per share for the year, down from their previous forecast of $2.99. The consensus estimate for MediWound’s current full-year earnings is ($2.49) per share.

A number of other brokerages have also recently issued reports on MDWD. Wall Street Zen raised MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $32.00 target price (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of MediWound in a report on Thursday, May 28th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, MediWound has a consensus rating of “Hold” and a consensus target price of $34.00.

MediWound Stock Down 0.1%

Shares of MDWD stock opened at $13.74 on Thursday. MediWound has a twelve month low of $13.54 and a twelve month high of $22.09. The company has a market cap of $176.58 million, a P/E ratio of -6.08 and a beta of 0.16. The business has a fifty day simple moving average of $16.43 and a 200 day simple moving average of $17.34.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.42. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $3.37 million. During the same period in the prior year, the company earned ($0.07) EPS.

Insiders Place Their Bets

In related news, Director David Morton Fox acquired 3,537 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was acquired at an average cost of $14.11 per share, for a total transaction of $49,907.07. Following the completion of the acquisition, the director directly owned 22,283 shares of the company’s stock, valued at approximately $314,413.13. This trade represents a 18.87% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 9.20% of the stock is owned by insiders.

Hedge Funds Weigh In On MediWound

A number of hedge funds and other institutional investors have recently made changes to their positions in MDWD. Quarry LP acquired a new position in shares of MediWound in the 4th quarter worth approximately $26,000. BNP Paribas Financial Markets grew its stake in MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the period. Russell Investments Group Ltd. grew its stake in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in MediWound during the fourth quarter worth approximately $109,000. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.